The BioPhorum CGT Personas and User Stories toolkit details the needs of all the key players involved in end-to-end cell and gene therapy (CGT) processes. It can be used by anyone who wishes to better understand how IT systems can support the manufacture and delivery of CGTs.
For biotech industries, Emerson offers fundamental automation solutions with quicker uptimes and more consistent batch quality.
Reliability of assets used in the manufacturing process is paramount for safe, efficient and effective operations. Unplanned asset failures, improper asset performance, poor maintenance planning, and untimely follow-through can cause shutdowns, under-utilized production equipment, deviations, or material/product losses.
At the recent conference for pharmaceutical and biotech manufacturers, Interphex 2012, Pharmaceutical Manufacturing magazine Editor in Chief Agnes Shanley discussed trends in the industry's use of process analytical technology (PAT) and quality by design (QbD) with...
It was just about a year ago that the U.S. Food and Drug Administration published their Guidance for Industry - Process Validation: General Principles and Practices. I caught up with Emerson's Heather Schwalje, a senior consultant on the Life Sciences industry team....
An Emerson fellow blogger, Alan Babbitt, and his Emerson Global Life Sciences Blog was first to the scene to cover a great Bioprocess International article, Hurry Up and Wait? The article, by Emerson senior Life Sciences industry consultant, Michalle Adkins, describes...
I caught up the other day with Emerson's Shenling Yang, who is a senior project execution engineer in the Life Sciences and Food & Beverage (LSFB) industry group. You may recall Shenling from earlier posts. She shared two pieces of news with me. The first is that...
Stay up to Date with the Latest News and Updates
Subscribe for Updates
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Our Global Community